A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2022-06-11

Summary

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole or palbociclib/fulvestrant.

• Phase: Phase 1

Details

• Lead Sponsor: Celcuity, Inc.; Pfizer
• Treatments: Estradiol; Fulvestrant; Gedatolisib; Letrozole; Palbociclib